2018 Drug Development Pharmaceutical Manufacturing 
Pharmaceutical Technology
JUNE 20, 2025
June 20, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook In March 2018, Health Canada approved Novartis’ therapy to treat individuals with HR+/HER2- advanced or metastatic breast cancer. In March 2018, Health Canada approved the therapy to treat individuals with HR+/HER2- advanced or metastatic breast cancer.
pharmaphorum
AUGUST 6, 2025
Skip to main content Wednesday 6 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JANUARY 9, 2024
Revolutionising quality control In the backdrop of stringent quality standards and regulatory demands inherent to pharmaceutical manufacturing, the addition of AI technologies introduce a paradigm shift. Integrative Analysis of Multi-Omics Data with Deep Learning: Challenges and Opportunities in Bioinformatics.
Quality Matters
MAY 21, 2024
Q: Since the discovery of nitrosamines in medicines in 2018, regulatory agencies and industry members around the world have taken swift action to prevent unacceptable levels of nitrosamine impurities from forming in pharmaceuticals. A: Following the discovery of nitrosamines in 2018, USP, U.S.
Pharmaceutical Technology
DECEMBER 6, 2022
Despite the current emphasis on biologic medicines, small molecule drugs still dominate the pharmaceutical manufacturing world. Within the small molecule landscape, several trends are shaping the industry’s future, one of the most notable being the rise of high-potency active pharmaceutical ingredients (HPAPIs).
Quality Matters
MAY 17, 2023
Paradigm Shift in Drug Development: Analytical Quality by Design and Analytical Procedure Life Cycle In today’s pharmaceutical manufacturing environment, companies face increasing pressure to respond to changing demands across the global medicines supply chain while still maintaining the quality of their drug products.
European Pharmaceutical Review
DECEMBER 21, 2022
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Environ Sci Technol 2018, 52, 4, 1725–1734 [link].
Expert insights. Personalized for you.
Let's personalize your content